Rhamnose (monohydrate)

Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas^[2][3][5].
In Vitro:Rhamnose (50 mM, 30 h) monohydrate can regulate the expression of P_rha target genes in Listeria monocytogenes^[1].
Rhamnose (1 mM) monohydrate can reduce the levels of pro-inflammatory interleukins and matrix metalloproteinases (MMPs) in a human dermal fibroblast (NHDF) skin aging model stimulated by advanced glycation end products (AGEs), thus possessing anti-aging potential^[2].
Rhamnose (0-300 μM, 1 h) monohydrate promotes phosphorylation of PKA substrate and HSL in SVF-derived adipocytes, stimulates PKA signaling and induces thermogenesis^[3].
In Vivo:Rhamnose (0.25-1 mg/mL (dissolve in water; 9 weeks; p.o.) or 300 mg/kg (7 days; i.p.)) monohydrate has anti-obesity effects in obese mice through stimulation of adipose dopamine receptors and thermogenesis^[3].
Rhamnose (5,-15 mg/kg; i.p.) monohydrate competitively inhibits the toxic effects of BEC on murine sarcoma 180 (S180) and reduces survival in sarcoma-bearing mice^[4].
Rhamnose (1-5 g/kg; once daily; 14 days; i.p.) monohydrate has antitumor activity in mice with Ehrlich’s solid tumor^[5].